Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy

被引：35
作者：
McGowan T.A. [1 ]
Zhu Y. [1 ]
Sharma K. [1 ]
机构：
[1] Dorrance Hamilton Res. Laboratories, Division of Nephrology, Thomas Jefferson University Hospital, Philadelphia, PA 19107
来源：
Current Diabetes Reports | 2004年 / 4卷 / 6期
基金：
美国国家卫生研究院;
关键词：
Diabetic Nephropathy; Idiopathic Pulmonary Fibrosis; Mesangial Cell; Renal Fibrosis; Diabetic Kidney Disease;
D O I：
10.1007/s11892-004-0055-z
中图分类号：
学科分类号：
摘要：
Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure. The identification that matrix accumulation is driven by transforming grcmdh factor-β (TGF-β) has led to a concerted effort to apply antifibrotic strategies for this disorder. Recent studies have not only demonstrated the beneficial effects of blocking TGF-β on matrix accumulation but have also found that blocking TGF-β may have important hemodynamic effects that are relevant to diabetic complications. In this article, we review the latest knowledge regarding the role of TGF-β in diabetic kidney disease and discuss available and novel therapeutic approaches. The role of a novel antifibrotic drug, pirfenidone, may have important clinical relevance to diabetic nephropathy. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：447 / 454
页数：7
相关论文
共 75 条
[1]  
Mauer S.M., Steffes M.W., Ellis E.N., Et al., Structural-functional relationships in diabetic nephropathy, J. Clin. Invest., 74, pp. 1143-1155, (1984)
[2]  
Harris R.D., Steffes M.W., Bilous R.W., Et al., Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes, Kidney Int., 40, pp. 107-114, (1991)
[3]  
Ziyadeh F.N., The extracellular matrix in diabetic nephropathy, Am. J. Kidney Dis., 22, pp. 736-744, (1993)
[4]  
Sharma K., Ziyadeh F.N., Hyperglycemia and diabetic kidney disease: The case for transforming growth factor-beta as a key mediator, Diabetes, 44, pp. 1139-1146, (1995)
[5]  
McGowan T., McCue P., Sharma K., Diabetic nephropathy, Clin. Lab. Med., 21, pp. 111-146, (2001)
[6]  
O'Bryan G., Hostetter T., The renal hemodynamic basis of diabetic nephropathy, Sem. Nephrol., 17, pp. 93-100, (1997)
[7]  
Steffes M.W., Osterby R., Chavers B., Mauer S.M., Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients, Diabetes, 38, pp. 1077-1081, (1989)
[8]  
Strutz F., Muller G., Interstitial pathomechanisms underlying progressive tubulointerstitial damage, Kidney Blood Press Res., 22, pp. 71-80, (1999)
[9]  
Steffes M.W., Schmidt D., McCrery R., Basgen J.M., Glomerular cell number in normal subjects and in type 1 diabetic patients, Kidney Int., 59, pp. 2104-2113, (2001)
[10]  
Steffes M.W., Bilous R.W., Sutherland D.E.R., Mauer S.M., Cell and matrix components of the glomerular mesangium in type I diabetes mellitus, Diabetes, 41, pp. 679-684, (1992)
12345678